Pfizer and BioNTech's, COVID-19 Vaccine to Be , Submitted for Emergency Authorization.<br />The vaccine created by the companies <br />is known as BNT162b2.<br />It is the first coronavirus <br />vaccine to be submitted <br />for approval by the Food and <br />Drug Administration (FDA). .<br />Filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world, Albert Bourla, Pfizer CEO, via CNN.<br />The phase three trial of the vaccine commenced in July <br />and had more than 43,000 participants.<br />The vaccine proved to <br />be 95 percent effective <br />with no safety concerns.<br />We now have a more complete picture of both the efficacy and safety profile of our vaccine, giving us confidence in its potential, Albert Bourla, Pfizer CEO, via CNN.<br />The FDA is expected to approve the vaccine, <br />which means it could be available for some <br />high-risk populations by the middle of December.<br />Wide-scale availability of <br />the vaccine is not expected <br />until sometime in 2021
